Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Fitzgerald

Showing results (601-610 of 629) with videos related to

Pageof 63
Sort By:
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Journal of Asthma and Allergy|January 20, 2022
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE StudyAndrew N Menzies-Gow, Claire McBrien, Bindhu Unni, et al.
Chest|April 22, 2021
Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma CohortLiam G Heaney, Luis Perez de Llano, Mona Al-Ahmad, et al.
BMC Medical Research Methodology|August 22, 2020
International severe asthma registry (ISAR): protocol for a global registryJ Mark FitzGerald, Trung N Tran, Marianna Alacqua, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 27, 2023
Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthmaLuis Perez-de-Llano, Ghislaine Scelo, G Walter Canonica, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Journal of Asthma and Allergy|October 28, 2022
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic TherapyWenjia Chen, Mohsen Sadatsafavi, Trung N Tran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 6, 2022
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe AsthmaCeleste M Porsbjerg, Andrew N Menzies-Gow, Trung N Tran, et al.
Intensive Care Medicine|July 12, 2021
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M Arabi, Anthony C Gordon, Lennie P G Derde, et al.
The New England Journal of Medicine|February 25, 2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19, Anthony C Gordon, Paul R Mouncey, et al.
Pageof 63

Showing results (601-610 of 629) with videos related to

Sort By:
Pageof 63
The New England Journal of Medicine|April 22, 2026
Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk OutpatientsChristopher C Butler, Andrew D Pinto, Victoria Harris, et al.
Journal of Asthma and Allergy|January 20, 2022
Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE StudyAndrew N Menzies-Gow, Claire McBrien, Bindhu Unni, et al.
Chest|April 22, 2021
Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma CohortLiam G Heaney, Luis Perez de Llano, Mona Al-Ahmad, et al.
BMC Medical Research Methodology|August 22, 2020
International severe asthma registry (ISAR): protocol for a global registryJ Mark FitzGerald, Trung N Tran, Marianna Alacqua, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 27, 2023
Impact of pre-biologic impairment on meeting domain-specific biologic responder definitions in patients with severe asthmaLuis Perez-de-Llano, Ghislaine Scelo, G Walter Canonica, et al.
Lancet (London, England)|December 25, 2022
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trialChristopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, et al.
Journal of Asthma and Allergy|October 28, 2022
Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic TherapyWenjia Chen, Mohsen Sadatsafavi, Trung N Tran, et al.
The Journal of Allergy and Clinical Immunology. in Practice|January 6, 2022
Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe AsthmaCeleste M Porsbjerg, Andrew N Menzies-Gow, Trung N Tran, et al.
Intensive Care Medicine|July 12, 2021
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialYaseen M Arabi, Anthony C Gordon, Lennie P G Derde, et al.
The New England Journal of Medicine|February 25, 2021
Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19, Anthony C Gordon, Paul R Mouncey, et al.
Pageof 63